ENLV · Enlivex Therapeutics Ltd.

Summary

Enlivex Ltd. reported full-year 2025 net income of $1.23 billion and diluted EPS of $25.48, driven by appreciation in treasury and treasury-related derivative assets totaling $2.31 billion as of December 31, 2025. This reflects the company's dual strategy in quality longevity therapeutics and prediction markets treasury, enhancing shareholder value through unrealized gains.

Key takeaways

• Net income of $1.23 billion for year ended December 31, 2025
• Diluted EPS of $25.48 for year ended December 31, 2025
• Total treasury and treasury-related derivative assets of $2.31 billion as of December 31, 2025
• Shareholders’ equity of $1.93 billion as of December 31, 2025
• Cash, cash equivalents, and short-term investments in digital assets of $30.0 million as of December 31, 2025